Streetbeat News

ZURA

Zura Bio Limited

https://zurabio.com

Industry

Biotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

In Friday's intraday session, several health care stocks showed significant movement. Biodexa Pharmaceuticals, Agenus, Sunshine Biopharma, Cullinan Therapeutics, ImmunityBio, and Zura Bio were among the gainers with notable percentage increases in their stock prices. Conversely, Nuwellis, IMAC Holdings, NKGen Biotech, Aclarion, Accolade, and X4 Pharmaceuticals experienced declines. Accolade's drop was highlighted alongside its Q4 earnings report release.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 4:31 pm

Zura Bio's stock is trading higher following the announcement of an oversubscribed $112.5 million private placement.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:36 pm

Zura Bio Limited (NASDAQ:ZURA) announced a $112.5M private placement of 20.1M Class A shares at $3.108 each to fund operations through 2027. The placement, led by Access Biotechnology and other major investors, aims to accelerate the development of tibulizumab for autoimmune diseases. The deal, expected to close on April 22, 2024, includes pre-funded warrants and is in compliance with Nasdaq rules. Piper Sandler, Guggenheim Securities, and Cantor are the lead placement agents.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 1:23 pm

Zura Bio announced Robert Lisicki as its new CEO and Director, succeeding founding CEO Dr. Someit Sidhu, who remains a Board Director. Lisicki brings nearly 30 years of R&D, commercial, and global executive experience, particularly in I&I therapies.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 10:11 am

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on Zura Bio (NASDAQ:ZURA) but has lowered the price target from $17 to $16.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:33 pm

Zura Bio reported a Q4 EPS loss of $(0.30), missing the consensus estimate of $(0.23) by 30.43%.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:22 pm

Zura Bio announced the appointment of Robert Lisicki as CEO, effective April 8, 2024. He succeeds Someit Sidhu, who will continue to be involved with the company as a non-independent director of the board.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 10:26 am

Zura Bio (NASDAQ:ZURA) reported a Q4 EPS loss of $(2.09), surpassing the $(2.99) estimate, marking a significant improvement from last year's $(141.97) loss per share. The company's cash position of $99.8M is expected to sustain operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 10:19 am

In Friday's intraday session, several healthcare stocks experienced significant movements. IMAC Holdings, Virios Therapeutics, Regencell Bioscience, Ontrak, Outlook Therapeutics, and Biolase were among the gainers, with IMAC Holdings leading with a 91.5% increase. On the downside, SINTX Techs, Nkarta, Cutera, 180 Life Sciences, Zura Bio, and Sangamo Therapeutics saw notable declines, with SINTX Techs dropping by 30.4%. Notably, Biolase, Nkarta, and Cutera's movements were influenced by their Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 5:31 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. Jin Medical International (ZJYL) saw a substantial increase of 72.5%, while NRX Pharmaceuticals (NRXP) led the losers with a 12.1% decrease. Other notable gainers include Panbela Therapeutics (PBLA), IN8bio (INAB), Reviva Pharmaceuticals (RVPH), CNS Pharma (CNSP), and Nexalin Technology (NXL). On the losing side, bluebird bio (BLUE), Senti Biosciences (SNTI), Motus GI Holdings (MOTS), Zura Bio (ZURA), and BioAtla (BCAB) also saw declines.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.